Pancreatic Cancer and Thromboembolism in the Ambulatory Community

  • Davida A Kornreich Department of Medicine, Columbia University Medical Center. New York, NY, USA
  • Muhammad Wasif Saif Department of Medicine, Columbia University Medical Center. New York, NY, USA
Keywords: Ambulatory Care, Carcinoma, Pancreatic Ductal, Hematinics, Venous Thromboembolism


Pancreatic exocrine adenocarcinoma is one of the most common malignancies associated with thromboembolism. The authors summarize the two abstracts (#368 and #273) presented at the 2012 ASCO Gastrointestinal Cancers Symposium which were focused on pancreatic thrombosis in ambulatory patients. In addition, they discuss the risk of thrombosis associated with malignancy, chemotherapy, and erythropoietin stimulating agents and the management and implications thereof.


Download data is not yet available.


JW Blom. High risk of venous thrombosis in patients with pancreatic cancer. European Journal of Cancer. Volume 52, Issue 3, Feb 2006, pgs 410-414.

HK Chew et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med, 166(4) (2006), p 458-464.

S Paneesha et al. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at oupatient DVT clinics. Thromb Haemost 2010; 103: 338–343

AA Khorana, CW Francis, E. Culakova, NM Kuderer, GH Lyman. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–4.

GH Lyman et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer. Journal of Clinical Oncology, Vol 25, No 34 (December 1), 2007: pp. 5490-5505

A Diab. Cancer-related venous thromboembolism: insight into underestimated risk factors. Hematol Oncol Stem Cell Ther 2010; 3(4): 191-195.

Ana Belen Ruperez Blanco, Andrés Jesús Muñoz Martin, Pilar Garcia Alfonso, Sonsoles Alvarez Suarez, Mercedes Cavanagh Podesta, Sara Custodio Cabello, et al. Incidence and prediction of venous thromboembolism (VTE) in ambulatory patients (pts) with pancreas cancer receiving chemotherapy. J Clin Oncol Abstract #368

Jay Lin, Mehul R. Dalal, Gregory Clayton Connolly, Alok A. Khorana. Evaluation of venous thromboembolism (VTE) risk among ambulatory patients with pancreatic cancer in a real-world setting. J Clin Oncol Abstract #273.

A Gerl. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs. 1994;5:607–614.

V Juneja, P Keegan, JE Gootenberg, MD Rothmann,YL Shen, KY Lee, KD Weiss, R Pazdur. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res. 2008 Jun 1;14(11):3242-7.

New York Presbyterian Hospital. New York, NY, USA
How to Cite
KornreichD., & SaifM. (2012). Pancreatic Cancer and Thromboembolism in the Ambulatory Community. JOP. Journal of the Pancreas, 13(2), 185-186.
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012